Physician profile
Frantz E Pierre
NPI 1710168042
$6,495.09
in general payments reported to CMS, 2019-2025
18 companies · $1,776 in 2025
The $1,776 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $615 · 2020: $288 · 2021: $387 · 2022: $611 · 2023: $1,231 · 2024: $1,587 · 2025: $1,776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,436 · Education: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,435.72 |
| Education | $158.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,183.71 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Alkermes, INC. | $1,165.43 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $596.28 | 2019-2025 | Invega Sustenna |
| Neurocrine Biosciences, INC. | $536.13 | 2019-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $474.50 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $465.86 | 2021-2025 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $435.84 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $321.49 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Lundbeck LLC | $237.95 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $236.18 | 2024-2025 | Fanapt, Hetlioz |
| Corium, LLC | $226.41 | 2023-2025 | Azstarys |
| Indivior INC. | $194.28 | 2019-2024 | Perseris |
| Axsome Therapeutics, INC. | $174.79 | 2024-2025 | Auvelity |
| Abbvie INC. | $88.04 | 2021-2025 | |
| Ironshore Pharmaceuticals INC. | $71.16 | 2019-2023 | Jornay Pm |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $42.36 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $30.11 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $14.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frantz Pierre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.